11 Important Questions about GlaxoSmithKline’s USD 3 Billion Fraud Settlement, Answered

• By: Staff Editor
• Date: July 12, 2012

GlaxoSmithKline, the British drug maker agreed to pay $3 Billion in fines for promoting its best-selling drugs for unapproved uses and failing to report safety data. The company also faces criminal charges and civic penalties for improper marketing of a half-dozen other drugs and for violating the government's Medicaid program. The fraud settlement includes $1bn in criminal fines and $2bn in civil fines.

This article explains 11 important questions arising from the fraud settlement by GSK.